Primary Immunodeficiency Disorders Market Size & Share 2026-2035

Primary Immunodeficiency (PID) Disease Market Size

The primary immunodeficiency (PID) disease market was valued at USD 8.20 billion in 2025, advanced to USD 8.72 billion in 2026, and is projected to expand at a 6.2% CAGR (2026–2035), reaching USD 15.01 billion by 2035.

The primary immunodeficiency (PID) disease market is shaped by a widening diagnosed patient base, recurring replacement-therapy demand, and a gradual shift toward curative care for selected ultra-rare disorders. Revenues encompass diagnosis, treatment, and clinical management for genetically determined immune disorders, including PID-indicated immunoglobulin therapies, transplantation, gene therapy, supportive care, and diagnostic services.

Primary Immunodeficiency (PID) Disease Market Trends, Growth Drivers & GMI Forecast Outlook

Expanding newborn screening and genetic workup are converting previously undiagnosed disease burden into treatable demand, while subcutaneous delivery is moving more care beyond hospital infusion suites. The outlook remains constrained by plasma economics, supply concentration, and the long regulatory path required to commercialize curative gene therapies.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Newborn screening affects the market differently from a one-time diagnostic intervention. For antibody-deficient patients, identification and treatment initiation establish a prolonged replacement-therapy relationship, making diagnosis infrastructure a durable source of recurring demand. The greatest incremental opportunity lies where large birth cohorts and specialist capacity are beginning to align, rather than in mature systems where screening capture is already extensive.

Gene therapy introduces a separate demand pathway centered on manufacturing readiness, referral concentration, and payer acceptance. Ex vivo approaches can create a high-value curative modality, but their commercial relevance depends on moving beyond academic treatment settings into reliable GMP supply, qualified centers, and workable reimbursement arrangements.

Delivery innovation is reinforcing the transition from institution-centered care to patient-managed treatment. Easier preparation, lower caregiver burden, and more flexible administration can improve persistence while reducing the operational friction that has historically limited broader use of subcutaneous immunoglobulin across diverse age groups.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Plasma-derived immunoglobulin has a supply profile unlike that of recombinant biologics. Donor recruitment, collection infrastructure, fractionation, and release testing introduce long lead times, so capacity cannot be adjusted quickly when diagnosed demand rises or collection conditions weaken. The resulting cost pressure is particularly consequential in healthcare systems that rely on centralized purchasing or imported supply.

Supply concentration turns a procurement issue into a treatment-access issue. Hospitals may protect established patients during shortages, yet delayed initiation for newly identified patients can slow conversion of diagnostic gains into realized therapy demand. Diversification initiatives can improve resilience over time, but local collection and fractionation capability require sustained policy support and capital investment.

For gene therapies, authorization is only one stage of commercialization. Long-term follow-up obligations, manufacturing comparability requirements, specialist-center readiness, and payer negotiation can prolong the gap between regulatory success and broad patient access. That burden favors developers with sufficient capital, technical depth, and rare-disease commercialization capability.

Primary Immunodeficiency (PID) Disease Market Segment Analysis

By Disease Type

The primary immunodeficiency (PID) disease market is led by antibody deficiencies, which generated USD 5.41 billion in 2025 and are projected to reach USD 9.46 billion by 2035. Their commercial prominence reflects the broad prevalence of conditions such as X-linked agammaglobulinemia, common variable immunodeficiency, and IgA deficiency, together with a frequent need for lifelong replacement therapy. In particular, delayed recognition of CVID creates a continuing flow of adult treatment initiations, supporting durable demand rather than a short treatment cycle.

Combined immunodeficiencies represented 15% of the market in 2025 and are expected to grow at a 7.5% CAGR (2026–2035). SCID-focused screening identifies patients early enough for urgent intervention, while transplant and gene-therapy advances expand the clinical value of specialized centers. This combination raises the strategic importance of referral networks, donor availability, and manufacturing access for curative modalities.

Complement deficiencies generated USD 656 million in 2025 and are projected to account for 8% of the market in 2035. These disorders have a more bounded commercial profile than antibody deficiencies, but their management can involve a complex mix of infection prevention, immunoglobulin support, and targeted therapy. Their trajectory depends on clinical stratification and the availability of therapies suited to specific pathway defects.

Phagocytic disorders accounted for 7% of the market in 2025 and are projected to reach USD 1.20 billion by 2035. For chronic granulomatous disease and related disorders, curative interventions can materially change treatment intensity and revenue mix. Greater use of HSCT, alongside the potential emergence of gene-based approaches, supports a more procedure-intensive model than that seen in routine replacement therapy.

Other PIDs generated USD 328 million in 2025. This category remains clinically heterogeneous, spanning immune dysregulation, innate-immunity defects, and autoinflammatory conditions. Therapeutic decisions are often individualized, limiting the standardized treatment pathways and scale efficiencies present in larger disease categories.

By Treatment Type

Immunoglobulin replacement therapy (IgRT) generated USD 7.22 billion in 2025 and is projected to reach USD 12.46 billion by 2035. IgRT remains the treatment foundation because it addresses the recurring antibody-replacement needs of a broad PID population and benefits from established reimbursement pathways. Its most important internal shift is from intravenous delivery toward SCIG, supported by greater patient autonomy, reduced reliance on infusion facilities, and payers' interest in lower-intensity care settings. SCIG recipients in the Jeffrey Modell Centers Network increased 378% between 2013 and 2021 ^{[1]Jeffrey Modell Centers Network. “Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network.” springer.com}.

Hematopoietic stem cell transplantation (HSCT) accounted for 8% of the market in 2025 and is anticipated to expand at a 7.5% CAGR (2026–2035). HSCT is becoming relevant across a broader set of severe PID indications as center expertise, donor pathways, conditioning strategies, and post-transplant management improve. The modality remains operationally demanding, however, because clinical outcomes depend on timing, patient condition, graft access, and specialized care capacity.

Gene therapy generated USD 82 million in 2025 and is projected to reach USD 600 million by 2035. The segment's outlook is tied to regulatory outcomes and the ability to scale viral-vector and cell-processing workflows without compromising product consistency. Even limited patient volumes can affect market mix because curative interventions concentrate substantial value in highly specialized treatment episodes.

Other treatments represented 3% of the market in 2025 and are expected to grow at a 9.3% CAGR (2026–2035). Enzyme replacement, antimicrobial prophylaxis, and supportive therapies remain clinically important where patients are unsuitable for transplantation or gene therapy, or require stabilization before definitive treatment. Their role is likely to remain complementary rather than displace the core IgRT franchise.

By Patient Age Group

The pediatric segment generated USD 3.12 billion in 2025 and is projected to account for 35% of total market revenue in 2035. Pediatric care carries particularly high clinical intensity where early identification of SCID requires prompt treatment planning. Screening expansion can improve the timing of intervention, while dose adjustment, infection prevention, and caregiver training sustain demand for specialized clinical support.

The adult segment accounted for 62% of the market in 2025 and is projected to reach USD 9.76 billion by 2035. Adult demand is underpinned by the long treatment duration associated with CVID and other chronic antibody deficiencies. Better recognition by general practitioners and immunologists can bring longstanding undiagnosed cases into specialist care, widening the treated population beyond the cohort identified through newborn screening.

By End-Use

Hospitals generated USD 3.61 billion in 2025 and are projected to account for 38% of market revenue in 2035. Hospitals remain indispensable for acute presentation, diagnosis, supervised IVIG administration, transplantation, and management of complex patients. Their declining relative role reflects a channel rebalancing rather than diminished clinical significance, as stable patients move into less resource-intensive care settings.

Specialty clinics accounted for 31% of the market in 2025 and are expected to grow at a 6.9% CAGR (2026–2035). These sites provide a commercially important bridge between hospital-based infusion and independent home administration. Their ability to deliver nursing support, monitor transitions, and manage adherence makes them valuable in markets where patients require structured support before assuming self-care responsibility.

Homecare and self-administration generated USD 1.80 billion in 2025 and are projected to reach USD 3.90 billion by 2035. The channel benefits directly from SCIG compatibility, device innovation, patient education, and reimbursement for home biologics. Its expansion is likely to be strongest where community nursing, digital patient support, and payer acceptance reduce the practical burden of self-infusion.

Other end-use settings represented a stable 3% market share in 2025. Long-term care and related outpatient settings retain a smaller but necessary role for patients whose functional status, comorbidities, or treatment complexity prevent routine self-administration. Their demand profile remains dependent on local care-delivery organization rather than broad changes in product choice.

Primary Immunodeficiency (PID) Disease Market Regional Analysis

North America Primary Immunodeficiency (PID) Disease Market Analysis

The primary immunodeficiency (PID) disease market in North America generated USD 3.53 billion in 2025 and is projected to reach USD 6.00 billion by 2035. The region benefits from established screening infrastructure, mature specialist networks, broad product availability, and comparatively developed reimbursement systems. Its commercial position is supported by both diagnosed prevalence and the capacity to manage long-duration IgRT across hospital, clinic, and homecare channels.

U.S.

The U.S. market generated USD 3.17 billion in 2025 and is projected to reach USD 5.34 billion by 2035. Its scale reflects a deep plasma collection ecosystem, broad immunoglobulin availability, and advanced adoption of SCIG self-administration. The policy and commercial environment supports manufacturer patient programs, specialty distribution, and continued movement from facility-based care to treatment at home.

Canada

Canada represented 8.0% of North American revenue in 2025 and is expected to grow at a 6.1% CAGR (2026–2035). A managed national supply model supports structured access, but reliance on externally sourced plasma leaves the system exposed to international supply conditions. Domestic collection initiatives and long-term supplier arrangements therefore remain strategically important for continuity of care.

Mexico

Mexico generated USD 70 million in 2025 and is expected to grow at a 7.8% CAGR (2026–2035). The market's opportunity rests on expansion of specialist immunology infrastructure and more consistent reimbursement inclusion. Improving diagnosis can translate into meaningful volume growth, although access will remain shaped by the division between public procurement and private specialty care.

Europe Primary Immunodeficiency (PID) Disease Market Analysis

Europe accounted for 26% of the market in 2025 and is projected to reach USD 3.60 billion by 2035. The region combines mature patient registries, strong plasma-product regulation, and high SCIG adoption with continuing concerns around supply security. National self-sufficiency programs, procurement structures, and local fractionation capabilities increasingly influence competitive access alongside product attributes.

Germany

Germany generated USD 341 million in 2025 and is projected to account for 16% of European revenue in 2035. Broad statutory reimbursement and an established fractionation base support a comparatively resilient commercial environment. Strong patient-organization activity and early SCIG adoption also reinforce the country's role as a key European market for home-based immunoglobulin delivery.

France

France accounted for 14% of European revenue in 2025 and is projected to generate USD 504 million by 2035. Centralized management of immunoglobulin access gives public authorities a strong role in prioritization and formulary policy. Domestic fractionation capability adds supply resilience, although demand management remains necessary when global availability tightens.

UK

The UK generated USD 256 million in 2025 and is projected to account for 12% of European revenue in 2035. National procurement and the move toward UK-sourced plasma processing strengthen the strategic focus on supply resilience. This framework gives suppliers with reliable domestic or regional sourcing a potential advantage in a market governed by structured public purchasing.

Italy

Italy accounted for 10% of European revenue in 2025 and is projected to generate USD 360 million by 2035. Its plasma self-sufficiency program and regional reference-center model support specialized PID care, but service delivery varies across the country. Addressing geographic differences in access remains central to realizing the clinical value of national supply initiatives.

Spain

Spain generated USD 171 million in 2025 and is expected to grow at a 5.3% CAGR (2026–2035). The extension of TREC-based screening can improve early detection, while patient advocacy continues to support diagnosis and reimbursement access. Commercial growth will depend on how consistently regional health systems translate these capabilities into treatment initiation.

Asia Pacific Primary Immunodeficiency (PID) Disease Market Analysis

Asia Pacific generated USD 1.89 billion in 2025 and is expected to grow at a 8.3% CAGR (2026–2035). The region's expansion is rooted in diagnostic development, rising specialist capacity, and broader healthcare coverage across large populations with substantial previously unrecognized disease burden. Heterogeneous payer systems and domestic sourcing policies require manufacturers to pursue country-specific access, pricing, and distribution strategies.

China

China generated USD 660 million in 2025 and is expected to grow at a 8.6% CAGR (2026–2035). Pilot newborn screening, expanding specialist awareness, and increasing fractionation capacity can broaden the treated population. At the same time, policy support for domestic plasma products raises the importance of local supply relationships and can make market entry more complex for multinational brands.

Japan

Japan accounted for 22% of Asia Pacific revenue in 2025 and is projected to generate USD 882 million by 2035. Universal insurance and a developed specialist network provide a strong platform for advanced treatment adoption. Japan's approval of HYQVIA expanded access to facilitated SCIG and introduced a more flexible dosing option for eligible patients ^{[5]BioPharma International. “Japan's MHLW Approves Takeda's HYQVIA Subcutaneous Injection to Treat Agammaglobulinemia or Hypogammaglobulinemia.” biopharminternational.com}.

India

India generated USD 283 million in 2025 and is expected to grow at a 9.0% CAGR (2026–2035). A large birth cohort, growing neonatal capability, and expanding pediatric immunology networks create meaningful diagnostic upside. The coexistence of domestic IVIG supply with premium private-sector demand will continue to shape how manufacturers segment products and access channels.

South Korea

South Korea accounted for 12% of Asia Pacific revenue in 2025 and is projected to generate USD 504 million by 2035. Comprehensive reimbursement and newborn screening underpin therapy access, while domestic fractionation activity can improve supply security. The market is well positioned to adopt specialized immunoglobulin formats where clinical benefits are clear and reimbursement remains supportive.

Australia

Australia generated USD 170 million in 2025 and is projected to account for 8.8% of Asia Pacific revenue in 2035. Government-funded access and nationally defined clinical-use criteria support equitable treatment availability. Its structured reimbursement environment makes program alignment and evidence-based positioning particularly important for immunoglobulin suppliers.

Latin America Primary Immunodeficiency (PID) Disease Market Analysis

Latin America generated USD 410 million in 2025 and is projected to reach USD 751 million by 2035. The region's potential is tempered by imported-product dependence, uneven rare-disease policy implementation, and variable public procurement capacity. Greater diagnostic recognition can expand need, but realized treatment demand will depend on supply allocation, budget protection, and more reliable access pathways.

Brazil

Brazil generated USD 185 million in 2025 and is projected to reach USD 338 million by 2035. Newborn screening expansion can support earlier diagnosis, while centralized public procurement provides an important route to treatment access. The practical consistency of supply nevertheless varies across state-level health systems, making distribution execution and public-sector engagement essential.

Middle East & Africa (MEA) Primary Immunodeficiency (PID) Disease Market Analysis

MEA generated USD 246 million in 2025 and is projected to account for 3% of the market in 2035. The region contains sharply different access environments, ranging from well-funded Gulf specialist systems to markets with limited diagnostic infrastructure. This variation means that disease burden alone does not determine commercial opportunity; center availability, public funding, and procurement reliability are decisive.

GCC

The GCC accounted for 60.2% of MEA revenue in 2025 and is projected to generate USD 270 million by 2035. Government-supported rare-disease programs, specialist centers, and centralized procurement make the GCC comparatively accessible within the broader region. Suppliers with strong institutional relationships and dependable supply can address a concentrated group of treatment centers serving complex patients.

Primary Immunodeficiency (PID) Disease Market Share & Competitive Landscape

The primary immunodeficiency (PID) disease market share structure is moderately concentrated, with the five leading participants-CSL Behring, Takeda, Grifols/Biotest, Octapharma, and ADMA Biologics-collectively holding 72.9% of the market in 2025.

Scale in plasma collection, fractionation, regulatory execution, and specialty patient support creates formidable entry barriers in IgRT. Competitive differentiation is increasingly shaped by the ability to pair supply security with delivery innovation, while gene therapy and HSCT-related capabilities establish a separate strategic position in curative care.

CSL Behring

CSL Behring held a 33.4% market share in 2025. Its portfolio, including Hizentra and Privigen, is supported by broad plasma collection and manufacturing capabilities. The company is positioned to benefit from durable IgRT demand and the continued preference for subcutaneous administration, particularly where homecare infrastructure supports self-management.

Takeda Pharmaceutical

Takeda held a 21.7% market share in 2025. HYQVIA provides differentiated facilitated SCIG administration, while Takeda's plasma-derived therapy capabilities support broad participation across the immunoglobulin market. The FDA approval of GAMMAGARD LIQUID ERC adds a ready-to-use low-IgA option for eligible PID patients and strengthens the company's portfolio in a clinically specific treatment niche ^{[4]Takeda. “Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content.” takeda.com}.

Biotest (Grifol Group)

Biotest, within the Grifols group, held a 6.5% market share in 2025. Its Next Level fractionation infrastructure and YIMMUGO commercialization expand its ability to compete in high-value immunoglobulin markets. Success will depend on manufacturing reliability, regulatory execution, and the ability to secure distribution in markets where established plasma franchises retain strong channel control.

Octapharma

Octapharma competes through its IVIG and SCIG portfolio, as well as an ability to tailor supply arrangements to regional procurement requirements. Its participation in UK-sourced plasma supply for NHS England illustrates the strategic value of localized sourcing where public purchasers prioritize supply resilience. Private ownership may also provide flexibility to reinvest in manufacturing and market-specific commercial programs.

ADMA Biologics

ADMA Biologics is a focused participant in PID-indicated SCIG through Asceniv. Its specialization gives the company a clear position in a market where clinical focus, specialty distribution, and patient support can matter alongside broader plasma scale. Maintaining momentum will depend on sustained access within the U.S. specialty-treatment ecosystem and continued execution in a competitive SCIG category.

Baxter International

Baxter International retains relevance through its immunology heritage, hospital relationships, and legacy presence in plasma-derived therapies. Although strategic realignment has reduced emphasis on direct PID product positioning, its institutional footprint remains relevant to procurement and care pathways adjacent to immunoglobulin treatment.

Bluebird Bio

Bluebird Bio represents the gene therapy dimension of the competitive landscape. Its experience with regulatory navigation, manufacturing, and reimbursement challenges in rare-disease gene therapy provides a useful commercial precedent for developers targeting curative PID indications, where clinical promise must be matched by durable access models.

Orchard Therapeutics

Orchard Therapeutics has deep technical experience in ex vivo hematopoietic stem cell gene therapy and previously held the Strimvelis marketing authorization. Its history underscores the operational difficulty of converting rare-disease gene therapy authorization into broad commercial access. Manufacturing expertise and regulatory knowledge remain strategically relevant as PID developers advance new curative programs.

F. Hoffmann-La Roche

F. Hoffmann-La Roche participates in the PID ecosystem through diagnostic capabilities relevant to immunological workup and genetic characterization. Diagnostic sophistication is increasingly important as care shifts toward earlier recognition and molecularly differentiated treatment decisions. Roche's broader personalized-medicine capabilities may become more relevant as targeted approaches develop for select immune disorders.

Miltenyi Biotec

Miltenyi Biotec supplies cell-processing technologies that support HSCT and ex vivo gene-therapy workflows. Its role is therefore embedded in the enabling infrastructure for curative treatment, rather than in finished immunoglobulin products. Expansion of specialized treatment centers could increase the strategic importance of this platform position.

Leadiant Biosciences

Leadiant Biosciences participates in ADA-SCID management through PEG-ADA therapy. As curative options become more available, enzyme replacement may increasingly serve as stabilization or bridging therapy for patients who are not immediately eligible for transplantation or gene therapy. This creates a need for commercial strategies that remain aligned with evolving treatment sequencing.

Medac

Medac participates through supportive therapies relevant to HSCT conditioning and transplant-center care. Its relationships within the transplant ecosystem give it exposure to the procedural side of PID treatment. Demand will be influenced by the expansion of curative-intent programs and the ability of centers to manage complex conditioning protocols safely.

Recent Industry Developments

Takeda receives U.S. FDA approval for GAMMAGARD LIQUID ERC in primary immunodeficiency: Takeda announced FDA approval for GAMMAGARD LIQUID ERC for replacement therapy in eligible patients with primary immunodeficiency. The ready-to-use liquid formulation is designed for intravenous or subcutaneous administration and addresses a clinical need among patients requiring low-IgA immunoglobulin treatment ^{[4]Takeda. “Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content.” takeda.com}.

Rarity PBC and AGC Biologics enter GMP manufacturing partnership for ADA-SCID gene therapy RDP-101: Rarity PBC and AGC Biologics announced a partnership covering GMP process development, validation, and manufacturing for RDP-101. The agreement highlights the growing importance of manufacturing readiness in determining whether curative ADA-SCID programs can progress from clinical development to commercial access ^{[2]AGC Biologics. “AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for 'Bubble Baby Disease'.” businesswire.com}.

Takeda's HYQVIA receives facilitated SCIG approval in Japan: Japan's Ministry of Health, Labour and Welfare approved HYQVIA for agammaglobulinemia and hypogammaglobulinemia, creating access to facilitated SCIG administration in the Japanese market. The approval broadens treatment-format choice for patients and supports the continued shift toward more flexible subcutaneous care ^{[5]BioPharma International. “Japan's MHLW Approves Takeda's HYQVIA Subcutaneous Injection to Treat Agammaglobulinemia or Hypogammaglobulinemia.” biopharminternational.com}.